NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions

Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat...

Related Keywords

Stephen Willard ,Molly Cogan ,Nrx Pharmaceuticals Inc Nasdaq ,Global Communications ,Drug Administration ,Nrx Pharmaceuticals Inc ,Nrx Pharmaceuticals ,Trademark Office ,Nrxp Nrx Pharmaceuticals ,Us Food Drug Administration ,Neurorx Inc ,Chief Executive Officer ,Breakthrough Therapy Designation ,Protocol Agreement ,Sub Acute Suicidality ,Special Protocol Agreement ,Securities Litigation Reform Act ,Nc ,